Q (haiku): For patients with the EML4-ALK fusion gene in lung cancer how do the different fusion variants affect their long-term quality of life and risk of developing a secondary cancer?

═ answer (success)
I appreciate your question, but I need to clarify what cBioPortal can and cannot help with here.

**What I can do:**
cBioPortal can show you the prevalence and characteristics of EML4-ALK fusion variants in lung cancer studies — which studies have fusion data, how many patients carry each variant, co-occurring mutations, and links to clinical and genomic data.

**What I cannot do:**
cBioPortal does not store:
- **Quality of life (QoL) data** — the database focuses on genomic alterations and basic clinical attributes (age, stage, survival times), not patient-reported outcomes or functional status
- **Secondary cancer risk** — this requires long-term follow-up data and causality assessment, which is not routinely captured in genomic studies
- **Clinical outcome predictions by fusion variant** — while some studies may record OS/DFS, cBioPortal is a research tool, not a clinical decision-support system, and I cannot interpret data for individual prognosis

**What you should consult instead:**
- **Clinical literature** — systematic reviews and prospective trials on EML4-ALK variants (e.g., differences in response to ALK inhibitors like crizotinib, alectinib, or brigatinib by breakpoint)
- **Clinical trials databases** — ClinicalTrials.gov for ongoing ALK-positive lung cancer studies
- **Oncology guidelines** — NCCN, ESMO, or institutional protocols for ALK-positive NSCLC management
- **Medical oncologist** — for personalized risk assessment and treatment planning

If you'd like to **explore EML4-ALK prevalence, co-mutations, or survival data in public lung cancer cohorts** (descriptive research), I'm happy to help with that. Let me know which studies interest you, and I can query the database.